Rheumatoid Arthritis Clinical Trial
Official title:
A Novel, Theory Based Intervention to Promote Engagement in Physical Activity in Early Rheumatoid Arthritis (PEPA-RA): Proof of Concept Study
People with rheumatoid arthritis have indicated that they would like better support to remain
physically active following diagnosis and would welcome a physical activity programmes
delivered outside of a secondary care setting by a physiotherapist. With patient input, and
based upon previous research in other long term conditions, a physical activity intervention
was developed by the researchers for delivery by musculoskeletal physiotherapists in a
primary care setting.
This proposed proof of concept study will investigate the new intervention and inform a
future randomised controlled pilot trial. Four Band 6 musculoskeletal physiotherapists will
be trained to deliver the intervention. Subsequently up to 32 patients with a recent
diagnosis of rheumatoid arthritis (6 -24 months previously) will be recruited. Each
physiotherapist will deliver the 12-week intervention package to a group of 6-8 participants.
The participants will be asked to complete some outcome measures at the beginning of the
12-week intervention and again at the end.
Following the 12-week programme some of the patients will be asked what they thought of the
programme and the outcome measures and whether they have any suggestions for improvement.
Those that did and did not complete the programme will be included to ensure a wide range of
views. The treating physiotherapists will also be asked about their experiences of delivering
the programme as well as what they thought of the training.
Based upon these findings the programme will be refined and if appropriate further funding
sought to carry out a pilot randomised controlled trial.
A novel, theory based intervention to promote engagement in physical activity in early
rheumatoid arthritis (PEPA-RA): proof of concept study.
People with rheumatoid arthritis (RA) do less physical activity (PA) than the general
population and this is associated with work disability and reduced physical function. High
intensity training and supervised exercise can improve physical function in RA, while PA
decreases chronic inflammation and reduces pain, all without adversely affecting disease
activity. Despite the benefits, patients do not maintain exercise beyond the supervised
intervention and benefits are not maintained.
People with RA report a range of barriers to PA and are often reluctant to participate for
fear of exacerbating their symptoms. It is therefore essential that they are provided with
appropriate support to overcome these barriers soon after diagnosis, in order to optimise PA,
minimise inappropriate health beliefs and prevent unnecessary reductions in function.
Patients have also expressed a desire for more information relating to exercise.
Physiotherapists are best placed to provide this support as their approach is person-centred,
taking into account the individual's health and wellbeing needs and supporting
self-management through patient education and the facilitation of behaviour change. Whilst
the National Institute for Health and Care Excellence (NICE) guidelines indicate that people
with RA should have access to specialist physiotherapy to encourage regular PA this rarely
occurs in practice with a third of patients waiting over a year for physiotherapy. The
British Society of Rheumatology suggests that conversations regarding health promotion,
including PA, need to occur early in the patient pathway and are best delivered via primary
care.
To explore the opinions of people with RA in relation to support for PA programmes the
investigators carried out focus groups. Based upon these findings, in combination with
existing evidence and input from patient research partners, the researchers designed an
intervention for delivery in a primary care setting for people with recently diagnosed RA.
The focus group participants were in agreement that the intervention should be delivered in
an accessible location within their local community. The intervention is informed by a
theoretical framework for health behaviour change. The overall purpose of this new
intervention is to support long term engagement with PA in order to optimise maintenance of
physical function. The researchers plan to investigate the effectiveness of the intervention
in a future trial, but initially need to carry out a proof of concept study.
Aim: to test the feasibility of a novel intervention and inform a future randomised
controlled pilot trial of the refined intervention.
Objectives:
- To explore acceptability and feasibility of the intervention to patients and
physiotherapists including the format, delivery method and location, content and support
materials.
- To explore the acceptability of the physiotherapists training package.
- To refine the physiotherapists training and patient intervention packages.
- To determine acceptability and completeness of all the outcome measures. Up to 36 people
with a recent diagnosis of RA will be recruited to take part in one of 4 PA intervention
groups with 6-8 participants per group.
Patients will be recruited from secondary care Rheumatology outpatient clinics. Nursing staff
will receive a familiarisation session about the study and be encouraged to briefly discuss
it with all recently diagnosed RA patients. If patients express interest in taking part, a
full information sheet will be provided. Those declining the trial will be offered a copy of
the 'Keep Moving' booklet published by Arthritis Research UK. Where possible, reasons for
declining will be gathered.
Those interested will receive a brief telephone screening interview at a time of their
convenience (conducted by the Research Fellow). During the telephone call, patients will be
given an opportunity to ask questions about the study. Patients who confirm verbally that
they would like to enter the study will be referred to the physiotherapists delivering the
intervention. Following screening and informed consent potential participants will be invited
to enrol in the study. Written consent will be obtained when the patients attend for the
initial session.
Four Band 6 musculoskeletal physiotherapists from primary care settings will be trained, via
two half day workshops, to deliver the PA intervention.
Physiotherapist Training will be led by a musculoskeletal physiotherapist with experience of
delivering similar interventions to groups of RA and OA patients, as well as practical
experience of working in a regional rheumatology centre. They will be supported by a
Rheumatology Clinical Specialist Physiotherapist as well as experts in the delivery of
similar PA health behaviour change interventions. Following training the four
physiotherapists will each deliver the intervention to a group of 6-8 people with a recent
diagnosis of RA (diagnosed 6 months to 2 years prior to recruitment).
The intervention consists of four group sessions and one individual session delivered over a
period of 12 weeks in a primary care setting. Each session includes patient education and
support for behaviour change as well as a supervised practical exercise component. The
intervention is based upon a combination of self-determination theory and COM-B framework
(capability, opportunity, motivation and behaviour) and employs motivational interviewing
techniques. Motivational interviewing has been used successfully by a range of health
professionals to promote behaviour change. The combination of group and individualised
sessions is intended to facilitate peer support (providing relatedness) and ensure that
participants are provided with individual support to meet specific needs (enhancing autonomy
and competence).
Week 0 and 2 (2 hours each): The group (n=6-8) intervention commences with 2 sessions to set
and review goals, facilitate engagement and motivation, create an autonomy supportive
environment and facilitate relatedness (connection with others 'like me').
Week 4 (45 mins): Individualised session at a location that is agreed between the patient and
physiotherapist. This will be guided by the patient's goals as well as practicalities faced
by the physiotherapist including insurance issues and travel time. Example locations for the
individual session may include the patient's home, a community gym or swimming pool.
Participants will be supported to identify community facilities for PA (opportunity). The
individualised session will facilitate discussion of individual barriers to PA and
identification of strategies to overcome them that may be unique to the individual and their
setting. Patients will be given the opportunity to invite a supportive 'other' to attend this
session.
Weeks 8 & 12 (90 mins/session): Group consolidation sessions include discussion on problem
solving in relation to barriers and setbacks, as well as relapse prevention. Due to the
flare-up and remission pattern of RA there are periods when continued PA at the usual level
is not practicable; recovery strategies and re-engagement methods are thus incorporated into
the intervention. These sessions will also include 30 minutes of supervised exercise.
Patients will be asked to complete a range of outcomes at baseline and 12 weeks. All
participants will be asked to attend for one hour prior to the week 0 session commencing and
remain for one hour after the week 12 session to allow time for completion of outcomes. The
Research Fellow will oversee the completion of the outcome measures to reduce the risk of
bias from the physiotherapist delivering the intervention. The purpose of including these
outcomes within this 'proof of concept' study is to explore their acceptability to patients,
as well as to provide an indication of the interventions potential for benefit. Acceptability
of the outcomes package (primary and secondary outcomes) will be explored through the
subsequent patient interviews (described below), as well as through the percentage of data
that is analysable. Our patient research partner completed the baseline patient reported
outcomes and reported that they only took 14 minutes. They felt that this would be acceptable
to most participants in the study in addition to the completion of the objective measures.
The secondary outcomes are those proposed for the future definitive study:
In addition to the intervention outcomes the following data will be collected:
- Reasons for declining to take participate in the intervention
- Patient attendance at each of the five sessions
- Adverse events - data collected by the treating physiotherapist based upon events
occurring during the sessions as well as events reported by the patient to have occurred
between sessions.
- Queries received by the research team from the treating physiotherapists will be logged.
Following the three-month intervention, qualitative semi-structured face to face individual
interviews will be undertaken with the four physiotherapists to explore their views regarding
the training and support provided; the method of delivery of the intervention including
number of sessions and time between sessions; content of the intervention and any other
issues relating to the training, the intervention or the future study that they deem
important. The physiotherapists will be encouraged to keep a reflective diary throughout the
intervention that they may refer to during the interview. The interviews will be carried out
by a Research Associate who has not had previous involvement in the study.
Patients will be invited to participate in semi-structured interviews (approximately n=12
dependent upon data saturation), in order to explore their experiences of the intervention,
the support material and outcome measures. They will also be asked about any other outcomes
that they experienced as a result of the study and about any contact that they made with the
rheumatology team during the study period. The aim will be to recruit 2-3 people from each
intervention group to participate including representation from those that dropped out before
week 12, males and females, and a range of ages. Where possible face to face interviews will
be carried out, but if this is not convenient for the patients then telephone interviews will
be offered. The Research Associate employed to carry out the interviews with the
physiotherapists will also conduct the patient interviews.
Quantitative outcome data will be reported using descriptive statistics including the
percentage of patients with analysable data.
Inductive thematic analysis will be carried out on the data from the physiotherapy and
patient interviews. The findings will then be used to help refine the physiotherapist
training and the intervention package. This information will ultimately inform the design of
a future randomised controlled pilot trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |